Clustering of human prion protein and α-synuclein oligomers requires the prion protein N-terminus.


Journal

Communications biology
ISSN: 2399-3642
Titre abrégé: Commun Biol
Pays: England
ID NLM: 101719179

Informations de publication

Date de publication:
09 07 2020
Historique:
received: 28 11 2019
accepted: 18 06 2020
entrez: 11 7 2020
pubmed: 11 7 2020
medline: 16 6 2021
Statut: epublish

Résumé

The interaction of prion protein (PrP) and α-synuclein (αSyn) oligomers causes synaptic impairment that might trigger Parkinson's disease and other synucleinopathies. Here, we report that αSyn oligomers (αSynO) cluster with human PrP (huPrP) into micron-sized condensates. Multivalency of αSyn within oligomers is required for condensation, since clustering with huPrP is not observed for monomeric αSyn. The stoichiometry of the heteroassemblies is well defined with an αSyn:huPrP molar ratio of about 1:1. The αSynO-huPrP interaction is of high affinity, signified by slow dissociation. The huPrP region responsible for condensation of αSynO, residues 95-111 in the intrinsically disordered N-terminus, corresponds to the region required for αSynO-mediated cognitive impairment. HuPrP, moreover, achieves co-clustering of αSynO and Alzheimer's disease-associated amyloid-β oligomers, providing a case of a cross-interaction of two amyloidogenic proteins through an interlinking intrinsically disordered protein region. The results suggest that αSynO-mediated condensation of huPrP is involved in the pathogenesis of synucleinopathies.

Identifiants

pubmed: 32647130
doi: 10.1038/s42003-020-1085-z
pii: 10.1038/s42003-020-1085-z
pmc: PMC7347944
doi:

Substances chimiques

Amyloid beta-Peptides 0
Prion Proteins 0
SNCA protein, human 0
alpha-Synuclein 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

365

Subventions

Organisme : European Research Council
ID : 726368
Pays : International

Références

Knowles, T. P., Vendruscolo, M. & Dobson, C. M. The amyloid state and its association with protein misfolding diseases. Nat. Rev. Mol. Cell Biol. 15, 384–396 (2014).
pubmed: 24854788 pmcid: 24854788 doi: 10.1038/nrm3810
Jucker, M. & Walker, L. C. Self-propagation of pathogenic protein aggregates in neurodegenerative diseases. Nature 501, 45–51 (2013).
pubmed: 3963807 pmcid: 3963807 doi: 10.1038/nature12481
Alam, P., Bousset, L., Melki, R. & Otzen, D. E. α-synuclein oligomers and fibrils: a spectrum of species, a spectrum of toxicities. J. Neurochem. 150, 522–534 (2019).
pubmed: 31254394 doi: 10.1111/jnc.14808 pmcid: 31254394
Cremades, N., Chen, S. W. & Dobson, C. M. Structural characteristics of α-synuclein oligomers. Int. Rev. Cell Mol. Biol. 329, 79–143 (2017).
pubmed: 28109332 doi: 10.1016/bs.ircmb.2016.08.010 pmcid: 28109332
Haass, C. & Selkoe, D. J. Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer’s amyloid β-peptide. Nat. Rev. Mol. Cell Biol. 8, 101–112 (2007).
pubmed: 17245412 doi: 10.1038/nrm2101 pmcid: 17245412
Kayed, R. et al. Common structure of soluble amyloid oligomers implies common mechanism of pathogenisis. Science 300, 486–489 (2003).
pubmed: 12702875 doi: 10.1126/science.1079469 pmcid: 12702875
Winner, B. et al. In vivo demonstration that α-synuclein oligomers are toxic. Proc. Natl. Acad. Sci. USA 108, 4194–4199 (2011).
pubmed: 21325059 doi: 10.1073/pnas.1100976108 pmcid: 21325059
Diogenes, M. J. et al. Extracellular α-synuclein oligomers modulate synaptic transmission and impair LTP via NMDA-receptor activation. J. Neurosci. 32, 11750–11762 (2012).
pubmed: 22915117 pmcid: 6703775 doi: 10.1523/JNEUROSCI.0234-12.2012
Ferreira, D. G. et al. α-synuclein interacts with PrPC to induce cognitive impairment through mGluR5 and NMDAR2B. Nat. Neurosci. 20, 1569–1579 (2017).
pubmed: 28945221 doi: 10.1038/nn.4648 pmcid: 28945221
Lashuel, H. A., Overk, C. R., Oueslati, A. & Masliah, E. The many faces of α-synuclein: from structure and toxicity to therapeutic target. Nat. Rev. Neurosci. 14, 38–48 (2013).
pubmed: 23254192 pmcid: 4295774 doi: 10.1038/nrn3406
Serrano-Pozo, A., Frosch, M. P., Masliah, E. & Hyman, B. T. Neuropathological alterations in Alzheimer disease. Cold Spring Harb. Perspect. Med. 1, a006189 (2011).
pubmed: 22229116 pmcid: 3234452 doi: 10.1101/cshperspect.a006189
Lee, H. J., Bae, E. J. & Lee, S. J. Extracellular α-synuclein-a novel and crucial factor in Lewy body diseases. Nat. Rev. Neurol. 10, 92–98 (2014).
pubmed: 24468877 doi: 10.1038/nrneurol.2013.275 pmcid: 24468877
Kim, C. et al. Neuron-released oligomeric α-synuclein is an endogenous agonist of TLR2 for paracrine activation of microglia. Nat. Commun. 4, 1562 (2013).
pubmed: 23463005 pmcid: 4089961 doi: 10.1038/ncomms2534
Prusiner, S. B. Prions. Proc. Natl. Acad. Sci. USA 95, 13363–13383 (1998).
pubmed: 9811807 doi: 10.1073/pnas.95.23.13363 pmcid: 9811807
Lauren, J., Gimbel, D. A., Nygaard, H. B., Gilbert, J. W. & Strittmatter, S. M. Cellular prion protein mediates impairment of synaptic plasticity by amyloid-beta oligomers. Nature 457, 1128–1132 (2009).
pubmed: 19242475 pmcid: 2748841 doi: 10.1038/nature07761
Chen, S., Yadav, S. P. & Surewicz, W. K. Interaction between human prion protein and amyloid-β (Aβ) oligomers: role Of N-terminal residues. J. Biol. Chem. 285, 26377–26383 (2010).
pubmed: 20576610 pmcid: 2924066 doi: 10.1074/jbc.M110.145516
Fluharty, B. R. et al. An N-terminal fragment of the prion protein binds to amyloid-β oligomers and inhibits their neurotoxicity in vivo. J. Biol. Chem. 288, 7857–7866 (2013).
pubmed: 23362282 pmcid: 3597823 doi: 10.1074/jbc.M112.423954
Kang, M., Kim, S. Y., An, S. S. & Ju, Y. R. Characterizing affinity epitopes between prion protein and β-amyloid using an epitope mapping immunoassay. Exp. Mol. Med. 45, e34 (2013).
pubmed: 23907583 pmcid: 3789258 doi: 10.1038/emm.2013.63
Younan, N. D., Sarell, C. J., Davies, P., Brown, D. R. & Viles, J. H. The cellular prion protein traps Alzheimer’s Aβ in an oligomeric form and disassembles amyloid fibers. FASEB J. 27, 1847–1858 (2013).
pubmed: 23335053 pmcid: 3767752 doi: 10.1096/fj.12-222588
Um, J. W. et al. Metabotropic glutamate receptor 5 is a coreceptor for Alzheimer Aβ oligomer bound to cellular prion protein. Neuron 79, 887–902 (2013).
pubmed: 24012003 pmcid: 3768018 doi: 10.1016/j.neuron.2013.06.036
Um, J. W. et al. Alzheimer amyloid-β oligomer bound to postsynaptic prion protein activates Fyn to impair neurons. Nat. Neurosci. 15, 1227–1235 (2012).
pubmed: 22820466 pmcid: 3431439 doi: 10.1038/nn.3178
Resenberger, U. K. et al. The cellular prion protein mediates neurotoxic signalling of β-sheet-rich conformers independent of prion replication. EMBO J. 30, 2057–2070 (2011).
pubmed: 21441896 pmcid: 3098494 doi: 10.1038/emboj.2011.86
Ulbrich, S. et al. Alterations in the brain interactome of the intrinsically disordered N-terminal domain of the cellular prion protein (PrPC) in Alzheimer’s disease. PLoS ONE 13, e0197659 (2018).
pubmed: 29791485 pmcid: 5965872 doi: 10.1371/journal.pone.0197659
La Vitola, P. et al. Cellular prion protein neither binds to α-synuclein oligomers nor mediates their detrimental effects. Brain 142, 249–254 (2019).
pubmed: 30601948 doi: 10.1093/brain/awy318 pmcid: 30601948
Kostylev, M. A. et al. Liquid and hydrogel phases of PrP(C) linked to conformation shifts and triggered by Alzheimer’s amyloid-β oligomers. Mol. Cell 72, 426–443.e412 (2018).
pubmed: 30401430 pmcid: 6226277 doi: 10.1016/j.molcel.2018.10.009
Rösener, N. S. et al. A d-enantiomeric peptide interferes with heteroassociation of amyloid-β oligomers and prion protein. J. Biol. Chem. 293, 15748–15764 (2018).
pubmed: 30131337 pmcid: 6187637 doi: 10.1074/jbc.RA118.003116
Chong, P. A. & Forman-Kay, J. D. Liquid−liquid phase separation in cellular signaling systems. Curr. Opin. Struct. Biol. 41, 180–186 (2016).
pubmed: 27552079 doi: 10.1016/j.sbi.2016.08.001
Wu, H. Higher-order assemblies in a new paradigm of signal transduction. Cell 153, 287–292 (2013).
pubmed: 23582320 pmcid: 3687143 doi: 10.1016/j.cell.2013.03.013
Altmeppen, H. C. et al. Proteolytic processing of the prion protein in health and disease. Am. J. Neurodegener. Dis. 1, 15–31 (2012).
pubmed: 23383379 pmcid: 3560451
Beland, M., Bedard, M., Tremblay, G., Lavigne, P. & Roucou, X. Aβ induces its own prion protein N-terminal fragment (PrPN1)-mediated neutralization in amorphous aggregates. Neurobiol. Aging 35, 1537–1548 (2014).
pubmed: 24602510 doi: 10.1016/j.neurobiolaging.2014.02.001 pmcid: 24602510
Nieznanska, H. et al. Identification of prion protein-derived peptides of potential use in Alzheimer’s disease therapy. Biochim. Biophys. Acta Mol. Basis Dis. 1864, 2143–2153 (2018).
pubmed: 29604335 doi: 10.1016/j.bbadis.2018.03.023 pmcid: 29604335
Giehm, L., Svergun, D. I., Otzen, D. E. & Vestergaard, B. Low-resolution structure of a vesicle disrupting α-synuclein oligomer that accumulates during fibrillation. Proc. Natl. Acad. Sci. USA 108, 3246–3251 (2011).
pubmed: 21300904 doi: 10.1073/pnas.1013225108 pmcid: 21300904
Lorenzen, N. et al. The role of stable α-synuclein oligomers in the molecular events underlying amyloid formation. J. Am. Chem. Soc. 136, 3859–3868 (2014).
pubmed: 24527756 doi: 10.1021/ja411577t pmcid: 24527756
Paslawski, W. et al. High stability and cooperative unfolding of α-synuclein oligomers. Biochemistry 53, 6252–6263 (2014).
pubmed: 25216651 doi: 10.1021/bi5007833 pmcid: 25216651
Brener, O. et al. QIAD assay for quantitating a compound’s efficacy in elimination of toxic Aβ oligomers. Sci. Rep. 5, 13222 (2015).
pubmed: 26394756 pmcid: 4585794 doi: 10.1038/srep13222
Duysens, L. N. The flattening of the absorption spectrum of suspensions, as compared to that of solutions. Biochim. Biophys. Acta 19, 1–12 (1956).
pubmed: 13304065 doi: 10.1016/0006-3002(56)90380-8 pmcid: 13304065
Gordon, D. J. & Holzwarth, G. Artifacts in the measured optic activity of membrane suspensions. Arch. Biochem. Biophys. 142, 481–488 (1971).
pubmed: 5550155 doi: 10.1016/0003-9861(71)90511-X pmcid: 5550155
Miles, A. J. & Wallace, B. A. Circular dichroism spectroscopy of membrane proteins. Chem. Soc. Rev. 45, 4859–4872 (2016).
pubmed: 27347568 doi: 10.1039/C5CS00084J pmcid: 27347568
Pantera, B. et al. PrPc activation induces neurite outgrowth and differentiation in PC12 cells: role for caveolin-1 in the signal transduction pathway. J. Neurochem. 110, 194–207 (2009).
pubmed: 19457127 doi: 10.1111/j.1471-4159.2009.06123.x pmcid: 19457127
Stuermer, C. A. et al. PrPc capping in T cells promotes its association with the lipid raft proteins reggie-1 and reggie-2 and leads to signal transduction. FASEB J. 18, 1731–1733 (2004).
pubmed: 15345693 doi: 10.1096/fj.04-2150fje pmcid: 15345693
Varma, R. & Mayor, S. GPI-anchored proteins are organized in submicron domains at the cell surface. Nature 394, 798–801 (1998).
pubmed: 9723621 doi: 10.1038/29563 pmcid: 9723621
Shin, Y. & Brangwynne, C. P. Liquid phase condensation in cell physiology and disease. Science 357, eaaf4382 (2017).
doi: 10.1126/science.aaf4382
Johnson, M., Coulton, A. T., Geeves, M. A. & Mulvihill, D. P. Targeted amino-terminal acetylation of recombinant proteins in E. coli. PLoS ONE 5, e15801 (2010).
pubmed: 21203426 pmcid: 3009751 doi: 10.1371/journal.pone.0015801
Falke, M. et al. α-synuclein-derived lipoparticles in the study of α-synuclein amyloid fibril formation. Chem. Phys. Lipids 220, 57–65 (2019).
pubmed: 30826264 pmcid: 6451039 doi: 10.1016/j.chemphyslip.2019.02.009
Wördehoff, M. M. et al. Opposed effects of dityrosine formation in soluble and aggregated α-synuclein on fibril growth. J. Mol. Biol. 429, 3018–3030 (2017).
pubmed: 28918091 pmcid: 5637163 doi: 10.1016/j.jmb.2017.09.005
Heukeshoven, J. & Dernick, R. Improved silver staining procedure for fast staining in PhastSystem Development Unit. I. Staining of sodium dodecyl sulfate gels. Electrophoresis 9, 28–32 (1988).
pubmed: 2466645 doi: 10.1002/elps.1150090106 pmcid: 2466645
Dawson, R. M. C., Elliott, D. C., Elliott, W. H. & Jones, K. M. Data for Biochemical Research (Oxford Science Publications, Oxford, UK, 1986).
Wördehoff, M. M. et al. Single fibril growth kinetics of α-synuclein. J. Mol. Biol. 427, 1428–1435 (2015).
pubmed: 25659910 doi: 10.1016/j.jmb.2015.01.020 pmcid: 25659910
Zhang, O., Kay, L. E., Olivier, J. P. & Forman-Kay, J. D. Backbone 1H and 15N resonance assignments of the N-terminal SH3 domain of drk in folded and unfolded states using enhanced-sensitivity pulsed field gradient NMR techniques. J. Biomol. NMR 4, 845–858 (1994).
pubmed: 7812156 doi: 10.1007/BF00398413 pmcid: 7812156
Findeisen, M., Brand, T. & Berger, S. A 1H-NMR thermometer suitable for cryoprobes. Magn. Reson. Chem. 45, 175–178 (2007).
pubmed: 17154329 doi: 10.1002/mrc.1941
Kay, L. E., Keifer, P. & Saarinen, T. Pure absorption gradient enhanced heteronuclear single quantum correlation spectroscopy with improved sensitivity. J. Am. Chem. Soc. 114, 10663–10665 (1992).
doi: 10.1021/ja00052a088
Schleucher, J., Sattler, M. & Griesinger, C. Coherence selection by gradients without signal attenuation: application to the three-dimensional HNCO experiment. Angew. Chem. Int. Ed. 32, 1489–1491 (1993).
doi: 10.1002/anie.199314891
Shaka, A. J., Keeler, J., Frenkiel, T. & Freeman, R. An improved sequence for broadband decoupling: WALTZ-16. J. Magn. Reson. 52, 335–338 (1983).
Delaglio, F. et al. NMRPipe: a multidimensional spectral processing system based on UNIX pipes. J. Biomol. NMR 6, 277–293 (1995).
doi: 10.1007/BF00197809
Johnson, B. A. & Blevins, R. A. NMR View: a computer program for the visualization and analysis of NMR data. J. Biomol. NMR 4, 603–614 (1994).
pubmed: 22911360 doi: 10.1007/BF00404272
Markley, J. L. et al. Recommendations for the presentation of NMR structures of proteins and nucleic acids. IUPAC-IUBMB-IUPAB Inter-Union Task Group on the Standardization of Data Bases of Protein and Nucleic Acid Structures Determined by NMR Spectroscopy. J. Biomol. NMR 12, 1–23 (1998).
pubmed: 9729785 doi: 10.1023/A:1008290618449 pmcid: 9729785
Friedrichs, M. S. A model-free algorithm for the removal of baseline artifacts. J. Biomol. NMR 5, 147–153 (1995).
pubmed: 22911463 doi: 10.1007/BF00208805 pmcid: 22911463
Dreier, L. & Wider, G. Concentration measurements by PULCON using X-filtered or 2D NMR spectra. Magn. Reson. Chem. 44, S206–S212 (2006).
pubmed: 16823904 doi: 10.1002/mrc.1838

Auteurs

Nadine S Rösener (NS)

Institute of Biological Information Processing (IBI-7) and JuStruct: Jülich Center for Structural Biology, Forschungszentrum Jülich, 52425, Jülich, Germany.
Institut für Physikalische Biologie, Heinrich-Heine-Universität Düsseldorf, 40204, Düsseldorf, Germany.

Lothar Gremer (L)

Institute of Biological Information Processing (IBI-7) and JuStruct: Jülich Center for Structural Biology, Forschungszentrum Jülich, 52425, Jülich, Germany.
Institut für Physikalische Biologie, Heinrich-Heine-Universität Düsseldorf, 40204, Düsseldorf, Germany.

Michael M Wördehoff (MM)

Institut für Physikalische Biologie, Heinrich-Heine-Universität Düsseldorf, 40204, Düsseldorf, Germany.

Tatsiana Kupreichyk (T)

Institute of Biological Information Processing (IBI-7) and JuStruct: Jülich Center for Structural Biology, Forschungszentrum Jülich, 52425, Jülich, Germany.
Institut für Physikalische Biologie, Heinrich-Heine-Universität Düsseldorf, 40204, Düsseldorf, Germany.

Manuel Etzkorn (M)

Institute of Biological Information Processing (IBI-7) and JuStruct: Jülich Center for Structural Biology, Forschungszentrum Jülich, 52425, Jülich, Germany.
Institut für Physikalische Biologie, Heinrich-Heine-Universität Düsseldorf, 40204, Düsseldorf, Germany.

Philipp Neudecker (P)

Institute of Biological Information Processing (IBI-7) and JuStruct: Jülich Center for Structural Biology, Forschungszentrum Jülich, 52425, Jülich, Germany.
Institut für Physikalische Biologie, Heinrich-Heine-Universität Düsseldorf, 40204, Düsseldorf, Germany.

Wolfgang Hoyer (W)

Institute of Biological Information Processing (IBI-7) and JuStruct: Jülich Center for Structural Biology, Forschungszentrum Jülich, 52425, Jülich, Germany. w.hoyer@fz-juelich.de.
Institut für Physikalische Biologie, Heinrich-Heine-Universität Düsseldorf, 40204, Düsseldorf, Germany. w.hoyer@fz-juelich.de.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH